Quarterly report · Q1
4574.TEDINET S100QQ1J
Period2023-01-01 → 2023-03-31
Filed2023-05-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.2bn | 2023-01-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥5.0bn | 2022-01-01 → 2022-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥621m | 2022-01-01 → 2022-03-31 | Cons. | Net sales |
| Operating income | −¥155m | 2023-01-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | −¥1.7bn | 2022-01-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | −¥242m | 2023-01-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥3.4bn | 2022-01-01 → 2022-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.7bn | 2022-01-01 → 2022-03-31 | Cons. | Ordinary income |
| Profit before tax | −¥242m | 2023-01-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | −¥1.7bn | 2022-01-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥243m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥4.9bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥1.7bn | 2022-01-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥243m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | −¥1.7bn | 2022-01-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥14.4bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥15.0bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥19.7bn | at 2022-03-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥6.5bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥7.0bn | at 2022-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥7.9bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥8.0bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥11.1bn | at 2022-03-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥3.1bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.1bn | at 2022-12-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥-5.59 | 2023-01-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-112.26 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-40.13 | 2022-01-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 54.5% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.5% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.4% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-03-31 | −¥241m |
| jpcrp040300-q1r_E22560-000Infection Control Businessreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥259m |
| jpcrp040300-q1r_E22560-000Infection Control Businessreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥259m |
| jpcrp040300-q1r_E22560-000Infection Control Businessreportable segment | segment profit | 2023-01-01 → 2023-03-31 | −¥124m |
| jpcrp040300-q1r_E22560-000Other Business Linesreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥1m |
| jpcrp040300-q1r_E22560-000Other Business Linesreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥1m |
| jpcrp040300-q1r_E22560-000Other Business Linesreportable segment | segment profit | 2023-01-01 → 2023-03-31 | −¥5m |
| jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥906m |
| jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥906m |
| jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥215m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-01-01 → 2023-03-31 | ¥1.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-01-01 → 2023-03-31 | ¥1.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-01-01 → 2023-03-31 | ¥85m |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-03-31 | −¥360m |
| jpcrp040300-q1r_E22560-000Infection Control Businessreportable segment | revenue | 2022-01-01 → 2022-03-31 | ¥39m |
| jpcrp040300-q1r_E22560-000Infection Control Businessreportable segment | revenue external | 2022-01-01 → 2022-03-31 | ¥39m |
| jpcrp040300-q1r_E22560-000Infection Control Businessreportable segment | segment profit | 2022-01-01 → 2022-03-31 | −¥1.3bn |
| jpcrp040300-q1r_E22560-000Other Business Linesreportable segment | revenue | 2022-01-01 → 2022-03-31 | ¥2m |
| jpcrp040300-q1r_E22560-000Other Business Linesreportable segment | revenue external | 2022-01-01 → 2022-03-31 | ¥2m |
| jpcrp040300-q1r_E22560-000Other Business Linesreportable segment | segment profit | 2022-01-01 → 2022-03-31 | −¥6m |
| jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segment | revenue | 2022-01-01 → 2022-03-31 | ¥579m |
| jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segment | revenue external | 2022-01-01 → 2022-03-31 | ¥579m |
| jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segment | segment profit | 2022-01-01 → 2022-03-31 | ¥13m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-01-01 → 2022-03-31 | ¥621m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-01-01 → 2022-03-31 | ¥621m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-01-01 → 2022-03-31 | −¥1.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 339
| Item | Context | Value | Unit |
|---|---|---|---|
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所プライム市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数100株 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Voting rights (text) | FilingDateInstant | Text · Plus | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)大幸薬品株式会社 | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)大阪府吹田市内本町三丁目34番14号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Debtors notes regarding overdraft contracts and or loan commitments (text) | CurrentQuarterInstant | Text · Plus | |
| Notes regarding write downs of inventories (text) | CurrentYTDDuration | Text · Plus | |
| Description of fact that quarterly statement of cash flows has not been prepared (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |